Nivolumab plus Ipilimumab in advanced melanoma
Antineoplastic Combined Chemotherapy Protocols
Programmed Cell Death 1 Receptor
Concurrent therapy with nivolumab and ipilimumab had a manageable safety profile and provided clinical activity that appears to be distinct from that in published data on monotherapy, with rapid and deep tumor regression in a substantial proportion of patients. (Funded by Bristol-Myers Squibb and Ono Pharmaceutical; ClinicalTrials.gov number, NCT01024231.).